Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Imaging Feasibility Study in Oestrogen Receptor Negative MEtastatic Breast Cancer by Targeting Integrin Alpha -v Beta 6

NCT06978478 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT06978478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06978478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Imaging Feasibility Study in Oestrogen Receptor Negative MEtastatic Breast Cancer by Targeting Integrin Alpha -v Beta 6
Lead sponsor
Queen Mary University of London
Phase
Not applicable
Overall status
Withdrawn
Start date
June 19, 2018
Completion date
July 27, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer